<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Lung Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Lung Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Lung cancer (Amsterdam, Netherlands)</journal-title></journal-title-group><issn pub-type="ppub">0169-5002</issn><issn pub-type="epub">1872-8332</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11787869</article-id><article-id pub-id-type="pmcid-ver">PMC11787869.1</article-id><article-id pub-id-type="pmcaid">11787869</article-id><article-id pub-id-type="pmcaiid">11787869</article-id><article-id pub-id-type="manuscript-id">NIHMS2043242</article-id><article-id pub-id-type="pmid">39615411</article-id><article-id pub-id-type="doi">10.1016/j.lungcan.2024.108040</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2043242</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2043242</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Patil</surname><given-names initials="T">Tejas</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="D">Dexiang</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watson</surname><given-names initials="A">Alexander</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names initials="M">Mandy</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nie</surname><given-names initials="Y">Yunan</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gibson</surname><given-names initials="A">Amanda</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dean</surname><given-names initials="ML">Michelle L</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yoder</surname><given-names initials="BA">Benjamin A.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="E">Eliza</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stalker</surname><given-names initials="M">Margaret</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aisner</surname><given-names initials="DL">Dara L.</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bunn</surname><given-names initials="PA">Paul A.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schenk</surname><given-names initials="EL">Erin L.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marmarelis</surname><given-names initials="ME">Melina E.</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bennati</surname><given-names initials="C">Chiara</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Navani</surname><given-names initials="V">Vishal</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yongchang</given-names></name><xref rid="A8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Camidge</surname><given-names initials="DR">D. Ross</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA</aff><aff id="A2"><label>b</label>Department of Biostatistics, University of Colorado School of Medicine, Aurora, CO, USA</aff><aff id="A3"><label>c</label>Yale Cancer Center, Yale University, New Haven, CT, USA</aff><aff id="A4"><label>d</label>Glans-Look Lung Cancer Research, Cumming School of Medicine, University of Calgary, Alberta, Canada</aff><aff id="A5"><label>e</label>Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA</aff><aff id="A6"><label>f</label>Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA</aff><aff id="A7"><label>g</label>Department of Hematology and Oncology, AUSL della Romagna, Ravenna, Italy</aff><aff id="A8"><label>h</label>Hunan Cancer Hospital, Xiangya School of Medicine, Changsha, China</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author at: University of Colorado Cancer Center, 1665 Aurora Court, MS F704, Aurora, CO 80045, USA. <email>tejas.patil@cuanschutz.edu</email> (T. Patil). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://twitter.com/TejasPatilMD" ext-link-type="uri">@TejasPatilMD</ext-link> (T. Patil)</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><volume>199</volume><issue-id pub-id-type="pmc-issue-id">481037</issue-id><fpage>108040</fpage><lpage>108040</lpage><pub-history><event event-type="nihms-submitted"><date><day>22</day><month>01</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>02</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-11 17:25:20.443"><day>11</day><month>02</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2043242.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">For patients with EGFR mutant NSCLC who progress on osimertinib, the clinical benefit of continuing osimertinib with next line platinum pemetrexed chemotherapy remains unknown.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">In this international, multi-center, retrospective cohort study, a total of 159 patients with EGFR mutant NSCLC who progressed on osimertinib and received platinum-pemetrexed therapy on progression from 2013 to 2023 were included. The data cutoff was December 31, 2023. Data analysis was conducted from January 2024 to June 2024. The primary endpoints were progression free survival (PFS) and overall survival (OS), analyzed using Kaplan-Meier methods. Multivariable Cox regression adjusting for patient-specific and cancer-specific factors was performed.</p></sec><sec id="S3"><title>Results:</title><p id="P3">421 patients with EGFR mutant NSCLC with progression on osimertinib were identified, of which159 patients who met pre-specified inclusion criteria were divided into two groups: Cohort 1 (osimertinib + platinum-pemetrexed) included 50 patients (median [IQR] age, 59 [30 &#8211; 83] years; 36 [72.0 %] female; 11 [22.4 %] Asian) and Cohort 2 (platinum-pemetrexed alone) included 109 patients (median [IQR] age, 54 [25 &#8211; 80] years; 62 [56.9 %] female; 74 [64.9 %] Asian). Most patients were never smokers (Cohort 1, 37 [74.0 %]; Cohort 2, 66 [60.6 %]). One third of patients had baseline brain metastases (Cohort 1, 19 [38.0 %]; Cohort 2, 36 [38.3 %]). Both cohorts had a median of two prior lines of anti-cancer therapy. The addition of bevacizumab or immune checkpoint inhibitors (ICI) to next-line platinum-pemetrexed chemotherapy was more common in Cohort 2 (bevacizumab use, 30.3 % vs 8.0 %, p = 0.002; ICI use, 33.0 % vs 2.0 %, p = 0.001). With a median duration of follow up of 30 months, there was a significant PFS benefit to continuing osimertinib with next line platinum pemetrexed chemotherapy (9.0 vs 4.5 months; HR 0.49, 95 % CI 0.32 &#8211; 0.74, p = 0.0032), also seen in subset analyses of patients who received first line osimertinib (n = 55, 11.0 vs 6.2 months; HR 0.41, 95 % CI 0.25 &#8211; 0.73, p = 0.002). Among patients with EGFR mutant NSCLC without brain metastases after progression on osimertinib, we found that continuing osimertinib with next line platinum pemetrexed significantly reduced the median time to CNS progression (n = 38; 7.0 vs 4.1 months; HR 0.47, 95 % CI 0.48 &#8211; 0.98, p = 0.01). After adjusted analysis, there was no significant OS difference between Cohorts 1 and 2 (19 months vs 13 months; HR 0.92, 95 % CI 0.60 &#8211; 1.39, p = 0.68).</p></sec><sec id="S4"><title>Conclusions and relevance:</title><p id="P4">For patients with EGFR mutant NSCLC who progress on osimertinib, there is a significant PFS, but not OS, benefit to continuing osimertinib with next line platinum pemetrexed chemotherapy. The continuation of osimertinib with next line platinum pemetrexed chemotherapy appears to reduce the risk of CNS progression.</p></sec></abstract><kwd-group><kwd>NSCLC</kwd><kwd>Tyrosine kinase inhibitor</kwd><kwd>EGFR</kwd><kwd>Osimertinib</kwd><kwd>Chemotherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S5"><label>1.</label><title>Introduction</title><p id="P5">Osimertinib is a third generation EGFR tyrosine kinase inhibitor (TKI) for patients with metastatic EGFR mutant non-small cell lung cancer (NSCLC) [<xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R2" ref-type="bibr">2</xref>]. Unfortunately, acquired resistance is inevitable and defining the optimal treatment strategies for patients who progress on osimertinib remains a clinical challenge. Different mechanisms of resistance to osimertinib have been well described [<xref rid="R3" ref-type="bibr">3</xref>&#8211;<xref rid="R7" ref-type="bibr">7</xref>], and adaptative therapies that target actionable mechanisms of resistance yield improved post-progression clinical outcomes [<xref rid="R8" ref-type="bibr">8</xref>&#8211;<xref rid="R13" ref-type="bibr">13</xref>]. Despite improved understanding of osimertinib resistance mechanisms, approximately forty-five percent of patients have no mechanism of resistance identified on progression [<xref rid="R14" ref-type="bibr">14</xref>]. For these patients, there is an unmet need in clarifying the optimal treatment strategy. Most guidelines recommend platinum-based chemotherapy alone as the next line of therapy after progression on osimertinib, with a historical median progression free survival (mPFS) of 4.4&#8211;5.5 months [<xref rid="R15" ref-type="bibr">15</xref>&#8211;<xref rid="R17" ref-type="bibr">17</xref>]. However, there appears to be benefit in continuing EGFR directed therapies with next line platinum pemetrexed chemotherapy. The MARIPOSA-2 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04988295" ext-link-type="uri">NCT04988295</ext-link>) found that the combination of amivantamab (an EGFR-MET bispecific monoclonal antibody) with platinum-pemetrexed chemotherapy after progression on osimertinib was associated with an improved mPFS (6.3 months vs 4.2 months, 0.48, 95 % CI 0.36&#8211;0.64, P &lt; 0.001), but no improved overall survival (OS) at first interim analysis (HR 0.77, 95 % CI 0.49 &#8211; 1.21, p = 0.25) [<xref rid="R18" ref-type="bibr">18</xref>]. While amivantamab with platinum-pemetrexed remains an option for patients with EGFR mutant NSCLC who progress on osimertinib, there are unique toxicities (such as infusion related reactions) with amivantamab that need to be considered. There are currently no randomized trial data describing the clinical benefit of continuing osimertinib with next line platinum pemetrexed chemotherapy versus switching to platinum pemetrexed chemotherapy alone. We performed an international, multi-center, retrospective analysis directly comparing these two strategies.</p></sec><sec id="S6"><label>2.</label><title>Materials and methods</title><sec id="S7"><label>2.1.</label><title>Patients and clinical data collection</title><p id="P6">The study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines following approved institutional review board (IRB) policies. Demographics, pathology, molecular testing, and treatment history were extracted from the electronic health record. All patients with EGFR mutant NSCLC from January 2013 &#8212; January 2023 who progressed on osimertinib and received next line platinum pemetrexed chemotherapy were eligible for analysis (<xref rid="SD1" ref-type="supplementary-material">Supplemental Fig. 1</xref>). Patients may have received osimertinib as first line therapy or after progression on prior 1st or 2nd generation EGFR TKIs. The primary endpoints were PFS and OS. PFS was defined as time from start of treatment to radiographic progression (per the investigator), death, or censoring at last follow up. OS was defined as time from start of treatment to death or censoring at last follow up. Surveillance body imaging (CT chest and abdomen) occurred every 3&#8211;4 months while on treatment. Surveillance MRI brain imaging was performed routinely across both cohorts, but the range of imaging assessments ranged from 3 months to annually. Concurrent bevacizumab or immune checkpoint inhibitor (ICI) use with next line platinum pemetrexed chemotherapy was captured. Receipt of these agents were treated as potential confounders. Exclusion criteria included: (1) non-metastatic disease, (2) absence of molecular profiling at diagnosis, (3) atypical EGFR mutations such as G719X, L861Q, or Exon 20 insertions, (4) non-platinum pemetrexed chemotherapy doublets, (5) receipt of a clinical trial agent, (6) incomplete follow up.</p></sec><sec id="S8"><label>2.2.</label><title>Statistical analyses</title><p id="P7">Demographic, clinical, and treatment characteristics were summarized and compared using paired t-tests (continuous variables) and Fisher&#8217;s exact test (for categorical variables). Unadjusted survival curves and corresponding medians were obtained with Kaplan-Meier methods. Cox Proportional Hazard models were used to assess the univariate associations between each survival outcome and the following pre-defined variables: prior lines of therapy, brain metastases, oligometastatic disease (defined as &#8804; 3 metastatic sites prior to receiving osimertinib), TP53 mutations, bevacizumab use, and ICI use. Martingale residuals were used to select the best functional form of prior lines of therapy. Schoenfeld and deviance residuals were further used to assess model fit. Hazard ratios, confidence intervals, corresponding p-values were obtained using robust standard errors. Statistical analyses were performed using GraphPad Prism software (version 10.2.3 for Windows, GraphPad Software, La Jolla, CA) and R Studio (version 4.4.0 for Windows, R Project, Vienna, Austria).</p></sec></sec><sec id="S9"><label>3.</label><title>Results</title><sec id="S10"><label>3.1.</label><title>Patient characteristics</title><p id="P8">421 patients with EGFR mutant NSCLC who progressed on osimertinib were identified across 5 cancer centers, of which 159 patients were eligible for analysis (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Eligible patients were divided into two cohorts: Cohort 1, osimertinib continued with next line platinum-pemetrexed chemotherapy (n = 50) and Cohort 2, platinum-pemetrexed chemotherapy alone (n = 109). The baseline characteristics are shown in <xref rid="T1" ref-type="table">Table 1</xref>. The median age at diagnosis for Cohorts 1 and 2 was 59 years (range, 30 &#8211; 83 years) and 54 years (range, 25 &#8211; 80 years) respectively. Most patients were never smokers (Cohort 1, 37 [74.0 %]; Cohort 2, 66 [60.6 %]). A third of patients in both cohorts had baseline brain metastases (Cohort 1, 19 [38.0 %]; Cohort 2 36 [38.3 %]). Both cohorts had a median of two prior lines of anti-cancer therapy. TP53 mutations were more common in Cohort 1 (17 [34 %] vs 5 [5 %], p &lt; 0.0001). The addition of bevacizumab and immune checkpoint inhibitors (ICI) to platinum pemetrexed chemotherapy was more common in Cohort 2 (bevacizumab use, 30.3 % vs 8.0 %, p = 0.002; ICI use, 33.0 % vs 2.0 %, p = 0.001).</p></sec><sec id="S11"><label>3.2.</label><title>Clinical outcomes</title><p id="P9">The median duration of follow up was 30.0 months. Radiographic progression as a reason for treatment discontinuation occurred in 139 patients. There was a significant difference in PFS between Cohorts 1 and 2 (9.0 vs 4.5 months; HR 0.49, 95 % CI 0.32 &#8211; 0.74, p = 0.0032; <xref rid="F2" ref-type="fig">Fig. 2A</xref>). Subset analyses of the main dataset was performed. Given the possible confounding effects of concurrent bevacizumab or ICI use with next line platinum pemetrexed chemotherapy, we performed a univariate survival analysis among patients who <italic toggle="yes">only</italic> received platinum pemetrexed chemotherapy after progression on osimertinib. There was a significant difference in PFS between Cohorts 1 and 2 (n = 98, 8.0 vs 4.0 months; HR 0.46, 95 % CI 0.29 &#8211; 0.71; p &lt; 0.0001; <xref rid="F2" ref-type="fig">Fig. 2C</xref>). Given that patients in this real-world cohort could have received prior 1st or 2<sup>nd</sup> generation EGFR TKIs, we conducted another univariate analysis among patients who received first line osimertinib, which also demonstrated a PFS benefit in continuing osimertinib with next line platinum pemetrexed chemotherapy (n = 55, 11.0 vs 6.2 months; HR 0.41, 95 % CI 0.25 &#8211; 0.73, p = 0.002; <xref rid="F3" ref-type="fig">Fig. 3A</xref>).</p><p id="P10">We sought to ascertain whether the presence or absence of brain metastases could influence our initial PFS observations. We performed a univariate subset analysis among patients with and without baseline brain metastases, which demonstrated that continuing osimertinib with platinum pemetrexed (Cohort 1) was associated with an improved PFS among patients without baseline brain metastases (n = 89; 9.0 vs 4.5 months; HR 0.50, 95 % CI 0.29 &#8211; 0.83, p = 0.0025; <xref rid="F4" ref-type="fig">Fig. 4A</xref>) and those with baseline brain metastases (n = 55, 7.0 vs 4.1 months; HR 0.56, 95 % CI 0.31 &#8211; 0.97, p = 0.04; <xref rid="F4" ref-type="fig">Fig. 4B</xref>). Given the variability in CNS surveillance patterns within this data set, we were unable to assess CNS PFS or CNS ORR. Within the University of Colorado cohort, we identified a subset of patients where CNS imaging every 3&#8211;4 months was performed (n = 67). In this group, we explored the cumulative incidence of CNS metastases among patients with EGFR mutant NSCLC who progressed on osimertinib. Among patients with EGFR mutant NSCLC <italic toggle="yes">without</italic> brain metastases after progression on osimertinib, we found that continuing osimertinib with next line platinum pemetrexed chemotherapy significantly improved the median time to CNS progression (n = 38; 7.0 vs 4.1 months; HR 0.47, 95 % CI 0.48 &#8211; 0.98, p = 0.01; <xref rid="F3" ref-type="fig">Fig. 3C</xref>). Among patients with EGFR mutant NSCLC <italic toggle="yes">with</italic> new brain metastases after progression on osimertinib, we found that continuing osimertinib with next line platinum pemetrexed chemotherapy was associated with a numeric, but not significant, improvement in the median time to CNS progression (n = 29; 25 vs 11 months; HR 0.32, 95 % CI 0.05 &#8211; 2.08, p = 0.10; <xref rid="F4" ref-type="fig">Fig. 4D</xref>).</p><p id="P11">There was a numeric, but not statistically significant, difference in OS between Cohorts 1 and 2 (19 months vs 13 months; HR 0.92, 95 % CI 0.60 &#8211; 1.39, p = 0.68; <xref rid="F2" ref-type="fig">Fig. 2B</xref>). Subset analyses of the main dataset was performed. There were no OS differences between Cohort 1 and 2 among patients who received first line osimertinib (n = 55, 23.0 vs 13.7 months; HR 0.59, 95 % CI 0.3 &#8211; 1.16, p = 0.14; <xref rid="F4" ref-type="fig">Fig. 4B</xref>), patients who received platinum pemetrexed chemotherapy alone, without concurrent bevacizumab or ICI use (n = 98, 14 months vs 12 months; HR 0.85, 95 % CI 0.53 &#8211; 1.38, p = 0.43; <xref rid="F2" ref-type="fig">Fig. 2D</xref>) or among patients with baseline brain metastases (n = 55, 13.0 vs 13.9 months; HR 1.03, 95 % CI 0.52 &#8211; 2.08, p = 0.91; <xref rid="SD1" ref-type="supplementary-material">Supplemental Fig. 2A</xref> and <xref rid="SD1" ref-type="supplementary-material">2B</xref>).</p><p id="P12">Multivariable modelling using lines of therapy, brain metastases, oligometastatic disease, bevacizumab use, or ICI use as covariates on the complete dataset was performed. No violation of proportional hazard assumption was observed (<xref rid="SD1" ref-type="supplementary-material">Supplemental Fig. 3</xref>). Number of prior anti-cancer treatments was significantly associated with worse PFS (HR 2.05, 95 % CI 1.35 &#8211; 3.13, p = 0.008, <xref rid="F5" ref-type="fig">Fig. 5A</xref>). The addition of bevacizumab with next line platinum pemetrexed chemotherapy was associated with a 44 % lower risk of death (HR 0.56, 95 % CI 0.33&#8211;&#8211;&#8211;0.90, p = 0.03, <xref rid="F5" ref-type="fig">Fig. 5B</xref>). The cumulative incidence of treatment discontinuation in the absence of progression or death was higher in Cohort 1 relative to Cohort 2 (22.7 % vs 4 %, p &lt; 0.004).</p></sec></sec><sec id="S12"><label>4.</label><title>Discussion</title><p id="P13">To our knowledge, this is the largest multi-institutional, international, series comparing the strategy of continuing osimertinib with next line platinum pemetrexed chemotherapy versus using platinum pemetrexed chemotherapy alone for patients with EGFR mutant NSCLC who progress on osimertinib. Our study has several novel findings of direct clinical relevance.</p><p id="P14">We demonstrate continuing osimertinib with next line platinum pemetrexed was associated with a significantly improved hazard ratio for progression (HR 0.49). This PFS benefit was replicable in subset analyses and mirrors findings = seen with other real-world studies [<xref rid="R19" ref-type="bibr">19</xref>&#8211;<xref rid="R22" ref-type="bibr">22</xref>], but builds on these studies by using a much larger dataset controlling for known confounders. Despite the heterogeneity in our real-world cohort, the patients who received platinum pemetrexed alone after progression on osimertinib (Cohort 2) had a median PFS of 4.1 months, which approximates the control arm of the MARIPOSA-2 clinical trial (median PFS 4.2 months) [<xref rid="R18" ref-type="bibr">18</xref>], suggesting that our control arm performed within range of what has been reported in the literature. The IMPRESS trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01544179" ext-link-type="uri">NCT01544179</ext-link>) found that continuing gefitinib (a 1st generation EGFR TKI) with platinum doublet chemotherapy did not improve subsequent PFS compared to use of platinum doublet chemotherapy alone [<xref rid="R23" ref-type="bibr">23</xref>]. However, subset analyses of this study did find notable PFS differences when patients were separated by the presence or absence of EGFR T790M resistance mutations. It remains an open question whether there are unique differences in post-progression PFS by continuing osimertinib with next line platinum pemetrexed when stratified by on-target and off-target mechanisms of resistance to osimertinib. This is being evaluated prospectively through the ongoing COMPEL [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04765059" ext-link-type="uri">NCT04765059</ext-link>], ORCHARD [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03944772" ext-link-type="uri">NCT03944772</ext-link>], SAFFRON [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05261399" ext-link-type="uri">NCT05261399</ext-link>], and Lung-MAP [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05364645" ext-link-type="uri">NCT05364645</ext-link>] clinical trials.</p><p id="P15">A major rationale for continuing osimertinib with platinum pemetrexed chemotherapy is the potential benefit from ongoing CNS exposure to osimertinib. Overall, we found that continuing osimertinib with platinum pemetrexed improved next line PFS in patients with and without a history of brain metastases. In a subset of patients in this study with detailed CNS surveillance, we also found that patients with EGFR mutant NSCLC who progressed on osimertinib with no detectable brain metastases on progression had a significantly lower cumulative risk of CNS progression when osimertinib was continued with platinum pemetrexed versus when platinum pemetrexed was used alone. In contrast, only a non-significant trend towards lower CNS progression was seen when patients who developed new brain metastases upon progression with osimertinib. The explanation for this may rest with the lack of detailed information captured in terms of prior CNS directed radiotherapy. In a single institution retrospective study from Heon and colleagues, gefitinib or erlotinib versus chemotherapy was associated with better CNS protection only in those without baseline brain metastases, but not among those with brain metastases, similar to our analysis [<xref rid="R24" ref-type="bibr">24</xref>]. The proposed explanation for lack of differential CNS benefit from the EGFR TKI in the setting of known brain metastases was the fact that most of their patients had received whole brain radiation therapy, thereby &#8216;sterilizing&#8217; the CNS and making a differential drug effect less obvious [<xref rid="R24" ref-type="bibr">24</xref>]. Our multivariable analysis found no association with PFS and brain metastases. Given that the cumulative risk of brain metastases among patients with EGFR mutant NSCLC is approximately 16 % per year [<xref rid="R25" ref-type="bibr">25</xref>], we suspect this finding is due to the competing risk associated with receiving multiple lines of prior therapy, which effectively extends the time horizon available to patients to develop CNS metastases.</p><p id="P16">There may be additive CNS protection offered with the combination of EGFR TKIs and platinum pemetrexed chemotherapy. This was shown in the GAP-Brain clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01951469" ext-link-type="uri">NCT01951469</ext-link>), which explored intracranial progression free survival between gefitinib with platinum pemetrexed chemotherapy versus gefitinib alone among untreated pa-tients with EGFR mutant NSCLC with brain metastases [<xref rid="R26" ref-type="bibr">26</xref>]. The hazard ratio for intracranial progression (HR 0.36) was superior among patients who received gefitinib with platinum pemetrexed versus those who received gefitinib alone. Third generation EGFR TKIs such as osimertinib and lazertinib have superior CNS control to gefitinib [<xref rid="R27" ref-type="bibr">27</xref>&#8211;<xref rid="R28" ref-type="bibr">28</xref>], and so exploring the intracranial benefit of 3rd generation EGFR TKIs with upfront platinum pemetrexed has also been explored. The FLAURA-2 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04035486" ext-link-type="uri">NCT04035486</ext-link>) demonstrated that patients with baseline brain metastases benefited from the combination of osimertinib with platinum pemetrexed in the first line setting with a median PFS of 24.9 months in this group [<xref rid="R29" ref-type="bibr">29</xref>]. Given that the reported CNS PFS of platinum pemetrexed chemotherapy alone ranges from 4&#8211;5 months [<xref rid="R30" ref-type="bibr">30</xref>&#8211;<xref rid="R31" ref-type="bibr">31</xref>], one of the possible benefits in continuing osimertinib with next line platinum pemetrexed chemotherapy is improved CNS control.</p><p id="P17">Multivariable modeling in our series found that the addition of bevacizumab with next line platinum pemetrexed chemotherapy was associated with a 44 % lower risk of death, suggesting that combining bevacizumab with platinum pemetrexed chemotherapy may be relevant. EGFR signaling can upregulate VEGF expression through various mechanisms, including activation of downstream signaling pathways such as MAPK and PI3K/AKT. However, clinical trials exploring the use of osimertinib with either bevacizumab or ramucirumab have had mixed results in demonstrating a sustained PFS or OS benefit with the combination of EGFR TKIs and anti-angiogenic agents [<xref rid="R32" ref-type="bibr">32</xref>&#8211;<xref rid="R35" ref-type="bibr">35</xref>]. Defining the exact role of anti-angiogenic agents (such as bevacizumab or ramucirumab) in combination with other anti-cancer therapies for patients with EGFR mutant NSCLC continues to evolve. Our data would suggest that bevacizumab combinations with platinum pemetrexed may have value among EGFR mutant NSCLC patients who progress on osimertinib, especially if these patients do not receive osimertinib with next line therapy. These findings need to be replicated, clarified, and better characterized with prospective large-scale studies.</p><p id="P18">In contrast with a retrospective series by Robinson and colleagues [<xref rid="R21" ref-type="bibr">21</xref>], we found a numeric, but not significant, OS benefit when osimertinib was continued with next line platinum pemetrexed. One unresolved question in the field is related to sequencing strategies of osimertinib and platinum pemetrexed chemotherapy. With FLAURA-2, we have data suggesting an improved PFS benefit with <italic toggle="yes">upfront</italic> osimertinib with platinum pemetrexed chemotherapy versus osimertinib alone. However, there is no consensus on whether upfront osimertinib with platinum pemetrexed chemotherapy (FLAURA-2) is a superior strategy to starting osimertinib <italic toggle="yes">followed by</italic> continuing osimertinib with next line platinum pemetrexed on progression. Our data show that among patients with EGFR mutant NSCLC who received first line osimertinib, the OS when osimertinib is continued with next line platinum pemetrexed was 23 months. As the FLAURA-2 OS data mature, our data can stand as a useful data point regarding the OS benefit for a sequential strategy (first line osimertinib <italic toggle="yes">followed by</italic> osimertinib with platinum pemetrexed on progression) versus an upfront approach (FLAURA-2; osimertinib with platinum pemetrexed as a first line treatment).</p><p id="P19">There are limitations with this paper. First, due to the variability in imaging assessments (inherent to a retrospective analysis), there is inbuilt heterogeneity in the capture of progression events that could influence PFS and OS assessments. However, as this is real world data, our findings reflect the way response (and progression) are captured in actual clinical practice. Second, given the variability of CNS surveillance patterns in a real-world dataset, we were unable to ascertain CNS PFS or CNS ORR, which would more directly address the question of intracranial benefit of continuing osimertinib with platinum pemetrexed. This is additionally complicated by limited information on the prior radiotherapy patterns (such as use of stereotactic radiosurgery or whole brain radiotherapy), which could confound our interpretation. Nonetheless, we performed a subset analysis among patients who were known to have CNS surveillance every 3&#8211;4 months and found striking differences in cumulative incidence of CNS progression. Finally, there was inconsistent molecular profiling on osimertinib progression, which limits our ability to both delineate the role of negative prognostic alterations (such as TP53 or Rb1 loss) and how certain osimertinib resistance mechanisms (such as C797S) contribute to post-progression outcomes [<xref rid="R36" ref-type="bibr">36</xref>&#8211;<xref rid="R37" ref-type="bibr">37</xref>].</p><p id="P20">In summary, patients with EGFR mutant NSCLC who progress on osimertinib derive a significant PFS benefit when osimertinib is continued with next line platinum pemetrexed chemotherapy. This strategy was associated with a numeric, but non-significant, improvement in overall survival. We found that continuing osimertinib with next line platinum pemetrexed improves the post-progression PFS among patients with and without a history of brain metastases. We also found that it reduces the cumulative CNS incidence among patients without brain metastases who progress on osimertinib. Future prospective studies can elucidate whether certain subgroups of patients with EGFR mutant NSCLC who progress on osimertinib, such as patients with with intracranial metastases or high-risk genomic alterations (such as dual tumor suppressor loss), may stand to most benefit with the combination of osimertinib with next line platinum pemetrexed chemotherapy.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2043242-supplement-1.pdf" id="d67e488" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S13"><title>Funding Sources</title><p id="P21">This research was supported by NIH/NCATS Colorado CTSA [UL1 TR002535]. This work was also supported by CCSG grant (P30CA46934) at the University of Colorado Cancer Center supporting the use of Genomics, Biostatistics, Bioinformatics, Molecular Correlates Laboratory, and Pathology Shared Resources.</p></ack><fn-group><fn id="FN1"><p id="P23">CRediT authorship contribution statement</p><p id="P24"><bold>Tejas Patil:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Resources, Funding acquisition, Formal analysis, Data curation, Conceptualization. <bold>Dexiang Gao:</bold> Methodology, Formal analysis, Data curation. <bold>Alexander Watson:</bold> Writing &#8211; review &amp; editing, Methodology, Data curation. <bold>Mandy Sakamoto:</bold> Data curation. <bold>Yunan Nie:</bold> Data curation. <bold>Amanda Gibson:</bold> Writing &#8211; review &amp; editing, Project administration, Methodology, Data curation. <bold>Michelle L Dean:</bold> Data curation. <bold>Benjamin A. Yoder:</bold> Data curation. <bold>Eliza Miller:</bold> Data curation. <bold>Margaret Stalker:</bold> Data curation. <bold>Dara L. Aisner:</bold> Validation, Resources, Methodology. <bold>Paul A. Bunn:</bold> Writing &#8211; review &amp; editing, Conceptualization. <bold>Erin L. Schenk:</bold> Writing &#8211; review &amp; editing. <bold>Melina E. Marmarelis:</bold> Writing &#8211; review &amp; editing, Supervision, Data curation. <bold>Chiara Bennati:</bold> Writing &#8211; review &amp; editing, Data curation. <bold>Vishal Navani:</bold> Writing &#8211; review &amp; editing, Supervision, Project administration, Investigation, Data curation, Conceptualization. <bold>Yongchang Zhang:</bold> Writing &#8211; review &amp; editing, Supervision, Project administration, Methodology, Data curation. <bold>D. Ross Camidge:</bold> Writing &#8211; review &amp; editing, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.</p></fn><fn fn-type="COI-statement" id="FN2"><p id="P25">Declaration of competing interest</p><p id="P26">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn><fn id="FN3"><p id="P27">Appendix A. Supplementary data</p><p id="P28"><xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 1.</xref>
<bold>Schema of the retrospective study design,</bold>
<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 2</xref>. <bold>Schoenfeld plots.</bold> Schoenfeld plots showing no violation of the proportional hazard assumption. A. Multivariable analysis of progression free survival. B. Multivariable analysis of overall survival. <xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 3</xref>. <bold>Overall survival among patients with and without brain metastases.</bold> A. Kaplan-Meier curve of overall survival from a subset of patients without a history of brain metastases. B. Kaplan-Meier curve of overall survival from a subset of patients without a history of brain metastases. Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1016/j.lungcan.2024.108040" ext-link-type="doi">https://doi.org/10.1016/j.lungcan.2024.108040</ext-link></p></fn></fn-group><sec sec-type="data-availability" id="S14"><title>Data availability</title><p id="P22">Deidentified aggregated data generated in this study are available upon request from the corresponding author. Please see Data Sharing Supplement Form.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soria</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Ohe</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Vansteenkiste</surname><given-names>J</given-names></name>, <etal/>, <article-title>Osimertinib in untreated EGFR-mutated advanced non&#8211;small-cell lung cancer</article-title>, <source>New Engl J Med</source>. <volume>378</volume> (<year>2017</year>) <fpage>113</fpage>&#8211;<lpage>125</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa1713137</pub-id>.<pub-id pub-id-type="pmid">29151359</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Papadimitrakopoulou</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Mok</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>J-Y</given-names></name>, <etal/>, <article-title>Osimertinib versus platinum&#8211;pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis</article-title>, <source>Ann Oncol</source>. <volume>31</volume> (<year>2020</year>) <fpage>1536</fpage>&#8211;<lpage>1544</lpage>, <pub-id pub-id-type="doi">10.1016/j.annonc.2020.08.2100</pub-id>.<pub-id pub-id-type="pmid">32861806</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>F</given-names></name>, <article-title>Resistance mechanisms to osimertinib and emerging therapeutic strategies in non-small cell lung cancer</article-title>, <source>Curr. Opin. Oncol</source>.. <volume>34</volume> (<issue>1</issue>) (<year>2022</year>) <fpage>54</fpage>&#8211;<lpage>65</lpage>, <pub-id pub-id-type="doi">10.1097/CCO.0000000000000805</pub-id>.<pub-id pub-id-type="pmid">34669648</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chmielecki</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <etal/>, <article-title>Candidate mechanisms of acquired resistance to first line osimertinib in EGFR-mutated advanced non-small cell lung cancer</article-title>, <source>Nat Commun</source>. <volume>14</volume> (<issue>1</issue>) (<year>2023</year>) <fpage>1070</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-023-35961-y</pub-id>.<pub-id pub-id-type="pmid">36849494</pub-id><pub-id pub-id-type="pmcid">PMC9971254</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Roper</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>JS</given-names></name>, <etal/>, <article-title>Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer</article-title>, <source>Cell Rep. Med</source>.. <volume>1</volume> (<issue>1</issue>) (<year>2020</year>) 100007, <pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100007</pub-id>.<pub-id pub-id-type="pmcid">PMC7263628</pub-id><pub-id pub-id-type="pmid">32483558</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kashima</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shibahara</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name>, <etal/>, <article-title>Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer</article-title>, <source>Cancer Res</source>. <volume>81</volume> (<issue>18</issue>) (<year>2021</year>) <fpage>4835</fpage>&#8211;<lpage>4848</lpage>, <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-2811</pub-id>.<pub-id pub-id-type="pmid">34247147</pub-id><pub-id pub-id-type="pmcid">PMC8448980</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Oxnard</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mileham</surname><given-names>KF</given-names></name>, <etal/>, <article-title>Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib</article-title>, <source>J. Am. Med. Assoc. Onc</source><volume>4</volume> (<issue>11</issue>) (<year>2018</year>) <fpage>1527</fpage>&#8211;<lpage>1534</lpage>, <pub-id pub-id-type="doi">10.1001/jamaoncol.2018.2969</pub-id>.<pub-id pub-id-type="pmcid">PMC6240476</pub-id><pub-id pub-id-type="pmid">30073261</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Martinez-Marti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Felip</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Matito</surname><given-names>J</given-names></name>, <etal/>, <article-title>Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)</article-title>, <source>Ann Oncol</source>. <volume>8</volume> (<issue>10</issue>) (<year>2017</year>) <fpage>2451</fpage>&#8211;<lpage>2457</lpage>, <pub-id pub-id-type="doi">10.1093/annonc/mdx396</pub-id>.<pub-id pub-id-type="pmcid">PMC5834054</pub-id><pub-id pub-id-type="pmid">28961841</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Guarneri</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Voon</surname><given-names>PJ</given-names></name>, <etal/>, <article-title>Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial</article-title>, <source>Lancet Oncol</source>. <volume>25</volume> (<issue>8</issue>) (<year>2024</year>) <fpage>989</fpage>&#8211;<lpage>1002</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(24)00270-5</pub-id>.<pub-id pub-id-type="pmid">39089305</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hartmaier</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Markovets</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>MJ</given-names></name>, <etal/>, <article-title>Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON</article-title>, <source>Cancer Discov</source>. <volume>13</volume> (<issue>1</issue>) (<year>2023</year>) <fpage>98</fpage>&#8211;<lpage>113</lpage>, <pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0586</pub-id>.<pub-id pub-id-type="pmid">36264123</pub-id><pub-id pub-id-type="pmcid">PMC9827108</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Choudhury</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Marra</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sui</surname><given-names>JSY</given-names></name>, <etal/>, <article-title>Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers</article-title>, <source>J Thorac Oncol</source>. <volume>18</volume> (<issue>4</issue>) (<year>2023</year>) <fpage>463</fpage>&#8211;<lpage>475</lpage>, <pub-id pub-id-type="doi">10.1016/j.jtho.2022.11.022</pub-id>.<pub-id pub-id-type="pmid">36494075</pub-id><pub-id pub-id-type="pmcid">PMC10249779</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Roy-Chowdhuri</surname><given-names>S</given-names></name>, <etal/>, <article-title>Brief report: clinical response, toxicity, and resistance mechanisms to osimertinib plus MET inhibitors in patients with EGFR-mutant MET-amplified NSCLC</article-title>, <source>JTO Clin Res Rep</source>. <volume>4</volume> (<issue>8</issue>) (<year>2024</year>) 100533, <pub-id pub-id-type="doi">10.1016/j.jtocrr.2023.100533</pub-id>.<pub-id pub-id-type="pmcid">PMC10462815</pub-id><pub-id pub-id-type="pmid">37649681</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Patil</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Staley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nie</surname><given-names>Y</given-names></name>, <etal/>, <article-title>The efficacy and safety of treating acquired MET resistance through combinations of parent and MET tyrosine kinase inhibitors in patients with metastatic oncogene-driven NSCLC</article-title>, <source>JTO Clin Res Rep</source>. <volume>5</volume> (<issue>2</issue>) (<year>2024</year>) 100637, <pub-id pub-id-type="doi">10.1016/j.jtocrr.2024.100637</pub-id>.<pub-id pub-id-type="pmcid">PMC10867444</pub-id><pub-id pub-id-type="pmid">38361741</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Leonetti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Minari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Perego</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Giovannetti</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tiseo</surname><given-names>M</given-names></name>, <article-title>Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer</article-title>, <source>Br. J. Cancer</source><volume>121</volume> (<issue>9</issue>) (<year>2019</year><month>Oct</month>) <fpage>725</fpage>&#8211;<lpage>737</lpage>, <pub-id pub-id-type="doi">10.1038/s41416-019-0573-8</pub-id>.<pub-id pub-id-type="pmid">31564718</pub-id><pub-id pub-id-type="pmcid">PMC6889286</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mok</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>MJ</given-names></name>, <etal/>; <article-title>Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer</article-title>. <source>N Engl J Med</source>. <volume>376</volume>(<issue>7</issue>):<fpage>629</fpage>&#8211;<lpage>640</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1612674</pub-id>.<pub-id pub-id-type="pmcid">PMC6762027</pub-id><pub-id pub-id-type="pmid">27959700</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mok</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>K</given-names></name>, <etal/>: <article-title>Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722</article-title>. <source>J Clin Oncol</source>. <volume>42</volume>(<issue>11</issue>):<fpage>1252</fpage>&#8211;<lpage>1264</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.23.01017</pub-id>.<pub-id pub-id-type="pmcid">PMC11095864</pub-id><pub-id pub-id-type="pmid">38252907</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>JCH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name>, <etal/>: <article-title>Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor&#8211;resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer</article-title>. <source>J Clin Oncol</source>. <year>2024</year>; [Epub &#8211; ahead of print]. doi: <pub-id pub-id-type="doi">10.1200/JCO.23.02747</pub-id>.<pub-id pub-id-type="pmcid">PMC11608596</pub-id><pub-id pub-id-type="pmid">39173098</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Passaro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal/>, <article-title>Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study</article-title>, <source>Ann Oncol</source>. <volume>35</volume> (<issue>1</issue>) (<year>2024</year>) <fpage>77</fpage>&#8211;<lpage>90</lpage>, <pub-id pub-id-type="doi">10.1016/j.annonc.2023.10.117</pub-id>.<pub-id pub-id-type="pmid">37879444</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gibson</surname><given-names>AJW</given-names></name>, <name name-style="western"><surname>Dean</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Litt</surname><given-names>I</given-names></name>, <etal/>, <article-title>Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib</article-title>, <source>Curr. Oncol</source>. <volume>31</volume> (<year>2024</year>) <fpage>2427</fpage>&#8211;<lpage>2440</lpage>, <pub-id pub-id-type="doi">10.3390/curroncol31050182</pub-id>.<pub-id pub-id-type="pmid">38785463</pub-id><pub-id pub-id-type="pmcid">PMC11120125</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Saw</surname><given-names>SPL</given-names></name>, <name name-style="western"><surname>Low</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>GGY</given-names></name>, <etal/>, <article-title>Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC</article-title>, <source>Lung Cancer</source>. <volume>193</volume> (<year>2024</year>) 107856, <pub-id pub-id-type="doi">10.1016/j.lungcan.2024.107856</pub-id>.<pub-id pub-id-type="pmid">38889498</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Robinson</surname><given-names>ND</given-names></name>, <name name-style="western"><surname>Canavan</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>PL</given-names></name>, <etal/>, <article-title>Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib</article-title>, <source>Clin Lung Cancer</source>. (<year>2024</year>) [Epub &#8211; ahead of print].doi: <pub-id pub-id-type="doi">10.1016/j.cllc.2024.09.006</pub-id>.<pub-id pub-id-type="pmid">39462746</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>White</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Piotrowska</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Stirling</surname><given-names>K</given-names></name>, <etal/>, <article-title>Combining osimertinib with chemotherapy in EGFR-Mutant NSCLC at progression</article-title>, <source>Clin Lung Cancer</source>. <volume>22</volume> (<year>2021</year>) <fpage>201</fpage>&#8211;<lpage>209</lpage>, <pub-id pub-id-type="doi">10.1016/j.cllc.2021.01.010</pub-id>.<pub-id pub-id-type="pmid">33610453</pub-id><pub-id pub-id-type="pmcid">PMC8205932</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mok</surname><given-names>TSK</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S-W</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y-L</given-names></name>, <etal/>, <article-title>Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation&#8211;Positive Non&#8211;Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses</article-title>, <source>J. Clin. Oncol</source><volume>35</volume> (<year>2017</year>) <fpage>4027</fpage>&#8211;<lpage>4034</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2017.73.9250</pub-id>.<pub-id pub-id-type="pmid">28968167</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Heon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yeap</surname><given-names>BY</given-names></name>, <name name-style="western"><surname>Lindeman</surname><given-names>NI</given-names></name>, <etal/>, <article-title>The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations</article-title>, <source>Clin Can Res</source>. <volume>18</volume> (<issue>16</issue>) (<year>2012</year>) <fpage>4406</fpage>&#8211;<lpage>4414</lpage>, <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0357</pub-id>.<pub-id pub-id-type="pmcid">PMC3682221</pub-id><pub-id pub-id-type="pmid">22733536</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gillespie</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Mustafa</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>GE</given-names></name>, <etal/>, <article-title>Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis</article-title>, <source>J Thorac Oncol</source>. <volume>18</volume> (<issue>12</issue>) (<year>2023</year>) <fpage>1703</fpage>&#8211;<lpage>1713</lpage>, <pub-id pub-id-type="doi">10.1016/j.jtho.2023.06.017</pub-id>.<pub-id pub-id-type="pmid">37392903</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>G</given-names></name>, <etal/>, <article-title>Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non&#8211;small cell lung cancer in patients with brain metastases The GAP BRAIN open-label, randomized, multicenter, Phase 3 study</article-title>, <source>J. Am. Med. Assoc. Netw Open</source><volume>6</volume> (<issue>2</issue>) (<year>2023</year>), <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.55050</pub-id>.<pub-id pub-id-type="pmcid">PMC9909498</pub-id><pub-id pub-id-type="pmid">36753281</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reungwetwattana</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>BC</given-names></name>, <etal/>: <article-title>CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source>. [Epub &#8211; ahead of print]. doi: <pub-id pub-id-type="doi">10.1200/JCO.2018.78.3118</pub-id>.<pub-id pub-id-type="pmid">30153097</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soo</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J-H</given-names></name>, <etal/>, <article-title>Central nervous system outcomes of lazertinib versus gefitinib in EGFR-Mutated advanced NSCLC: a LASER301 subset analysis</article-title>, <source>J Thorac Oncol</source>. <volume>18</volume> (<issue>12</issue>) (<year>2023</year>) <fpage>1756</fpage>&#8211;<lpage>1766</lpage>, <pub-id pub-id-type="doi">10.1016/j.jtho.2023.08.017</pub-id>.<pub-id pub-id-type="pmid">37865896</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Planchard</surname><given-names>D</given-names></name>, <name name-style="western"><surname>J&#228;nne</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <etal/>, <article-title>Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC</article-title>, <source>N Engl J Med</source>. <volume>389</volume> (<issue>21</issue>) (<year>2023</year>) <fpage>1935</fpage>&#8211;<lpage>1948</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2306434</pub-id>.<pub-id pub-id-type="pmid">37937763</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Barlesi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gervais</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lena</surname><given-names>H</given-names></name>, <etal/>, <article-title>Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07&#8211;01)</article-title>, <source>Ann Oncol</source>. <volume>22</volume> (<issue>11</issue>) (<year>2011</year>) <fpage>2466</fpage>&#8211;<lpage>2470</lpage>, <pub-id pub-id-type="doi">10.1093/annonc/mdr003</pub-id>.<pub-id pub-id-type="pmid">21321089</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bailon</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Chouahnia</surname><given-names>AA</given-names></name>, <etal/>, <article-title>Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma</article-title>, <source>Neuro Oncol</source>. <volume>14</volume> (<issue>4</issue>) (<year>2012</year>) <fpage>491</fpage>&#8211;<lpage>495</lpage>, <pub-id pub-id-type="doi">10.1093/neuonc/nos004</pub-id>.<pub-id pub-id-type="pmid">22362813</pub-id><pub-id pub-id-type="pmcid">PMC3309855</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Akamatsu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Toi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hayashi</surname><given-names>H</given-names></name>, <etal/>, <article-title>Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M&#8211;mutated non&#8211;small cell lung cancer previously treated with epidermal growth factor receptor&#8211;tyrosine kinase inhibitor</article-title>, <source>J. Am. Med. Assoc. Oncol</source><volume>7</volume> (<year>2021</year>) <fpage>386</fpage>&#8211;<lpage>394</lpage>, <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.6758</pub-id>.<pub-id pub-id-type="pmcid">PMC7791398</pub-id><pub-id pub-id-type="pmid">33410885</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kenmotsu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wakuda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>K</given-names></name>, <etal/>, <article-title>Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study</article-title>, <source>J Thorac Oncol</source>. <volume>17</volume> (<issue>9</issue>) (<year>2022</year>) <fpage>1098</fpage>&#8211;<lpage>1108</lpage>, <pub-id pub-id-type="doi">10.1016/j.jtho.2022.05.006</pub-id>.<pub-id pub-id-type="pmid">35636696</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="confproc"><name name-style="western"><surname>Yoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Terufumi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakahara</surname><given-names>Y</given-names></name>, <etal/>: <source>OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer</source> [abstract 8613]. Abstract presented at <conf-name>ASCO Annual Meeting</conf-name>; <conf-date>May 31 &#8211; June 4, 2024</conf-date>; <conf-loc>Chicago, IL, USA</conf-loc>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2024.42.16_suppl.8613</pub-id>.</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Le</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Shum</surname><given-names>E</given-names></name>, <etal/>: <article-title>A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na&#239;ve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)</article-title>. <source>J Clin Oncol</source>. <year>2024</year>; [Epub &#8211; ahead of print]. doi: <pub-id pub-id-type="doi">10.1200/JCO.24.00533</pub-id>.<pub-id pub-id-type="pmcid">PMC11776886</pub-id><pub-id pub-id-type="pmid">39378386</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Passaro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>J&#228;nne</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Mok</surname><given-names>T</given-names></name>, <etal/>, <article-title>Overcoming therapy resistance in EGFR-mutant lung cancer</article-title>, <source>Nat Cancer</source>. <volume>2</volume> (<year>2021</year>) <fpage>377</fpage>&#8211;<lpage>391</lpage>, <pub-id pub-id-type="doi">10.1038/s43018-021-00195-8</pub-id>.<pub-id pub-id-type="pmid">35122001</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Choudhury</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Marra</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sui</surname><given-names>JSY</given-names></name>, <etal/>, <article-title>Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers</article-title>, <source>J Thorac Oncol</source>. <volume>18</volume> (<year>2023</year>) <fpage>463</fpage>, <pub-id pub-id-type="doi">10.1016/j.jtho.2022.11.022</pub-id>.<pub-id pub-id-type="pmid">36494075</pub-id><pub-id pub-id-type="pmcid">PMC10249779</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p id="P29">CONSORT diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2043242-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p id="P30">Progression free survival and overall survival. A. Kaplan-Meier curve of progression free survival of all patients in the dataset. B. Kaplan-Meier curve of overall survival of all patients in the dataset. C. Kaplan-Meier curve of progression free survival from a subset of patients who only received platinum pemetrexed chemotherapy (without concurrent bevacizumab or immune checkpoint inhibitors). D. Kaplan-Meier curve of overall survival from a subset of patients who only received platinum pemetrexed chemotherapy (without concurrent bevacizumab or immune checkpoint inhibitors).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2043242-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p id="P31">Progression free survival and overall survival: subset analysis of patients with progression on first line osimertinib. A. Kaplan-Meier curve of progression free survival of a subset of patients treated with first line osimertinib. B. Kaplan-Meier curve of overall survival of a subset of patients treated with first line osimertinib.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2043242-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Fig. 4.</label><caption><p id="P32">CNS specific survival curves. A. Kaplan-Meier curve of progression free survival from a subset of patients without a history of brain metastases. B. Kaplan-Meier curve of progression free survival from a subset of patients with a history of brain metastases. C. Cumulative incidence of CNS progression among a subset of patients with serial brain imaging without brain metastases after progression on osimertinib. D. Cumulative incidence of CNS progression among a subset of patients with serial brain imaging with brain metastases after progression on osimertinib.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2043242-f0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Fig. 5.</label><caption><p id="P33">Forest plots. A. Forest plot of progression free survival. B. Forest plot of overall survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2043242-f0005.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p id="P34">Baseline characteristics of the cohorts evaluated in this study.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Cohort 1 (Osimertinib + Platinum pemetrexed) N = 50, n (%)</th><th align="left" valign="top" rowspan="1" colspan="1">Cohort 2 (Platinum pemetrexed) N = 109, n (%)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p-value</italic>
</th></tr><tr><th align="left" valign="top" colspan="4" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Median age at diagnosis, years (range)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">59.0 (30.0, 83.0)</td><td align="left" valign="top" rowspan="1" colspan="1">54.0 (25.0, 80.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Female</td><td align="left" valign="top" rowspan="1" colspan="1">36 (72.0)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (56.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Male</td><td align="left" valign="top" rowspan="1" colspan="1">14 (28.0)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (43.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&lt; 0.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Non-Asian</td><td align="left" valign="top" rowspan="1" colspan="1">38 (77.6)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (32.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Asian</td><td align="left" valign="top" rowspan="1" colspan="1">11 (22.4)</td><td align="left" valign="top" rowspan="1" colspan="1">74 (67.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Smoking Status</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Never</td><td align="left" valign="top" rowspan="1" colspan="1">37 (74.0)</td><td align="left" valign="top" rowspan="1" colspan="1">66 (60.6)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Former - light<sup><xref rid="TFN1" ref-type="table-fn">1</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">8 (16.0)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (11.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Former - heavy</td><td align="left" valign="top" rowspan="1" colspan="1">5 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (27.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>EGFR mutation</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Exon 19 deletion</td><td align="left" valign="top" rowspan="1" colspan="1">32 (64.0)</td><td align="left" valign="top" rowspan="1" colspan="1">70 (64.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;L858R</td><td align="left" valign="top" rowspan="1" colspan="1">18 (36.0)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (35.8)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TP53</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">17 (34.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">22 (44.0)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (54.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">11 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (41.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Clinical profile</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Brain metastases</td><td align="left" valign="top" rowspan="1" colspan="1">19 (38.0)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (38.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Oligometastatic disease<sup><xref rid="TFN2" ref-type="table-fn">2</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">16 (32.0)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (44.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Prior anti-cancer therapies</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Prior lines of anti-cancer therapy, median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (1.0, 5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (1.0, 4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.842</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;First line osimertinib</td><td align="left" valign="top" rowspan="1" colspan="1">23 (46)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Prior EGFR TKIs<sup><xref rid="TFN3" ref-type="table-fn">3</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">19 (38)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (19)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Prior chemotherapy<sup><xref rid="TFN4" ref-type="table-fn">4</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">9 (18)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Concurrent agents</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Bevacizumab</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (30.3)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Immune checkpoint inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (33.0)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>1</label><p id="P35">Light smoker defined as &#8804; 10 pack years.</p></fn><fn id="TFN2"><label>2</label><p id="P36">Oligometastatic disease is defined as &#8804; 3 metastatic sites at diagnosis.</p></fn><fn id="TFN3"><label>3</label><p id="P37">Patients may have also received prior 1st or 2nd generation EGFR TKIs (such as erlotinib, gefitinib, icotinib, afatinib, or dacomitinib) prior to receiving osimertinib.</p></fn><fn id="TFN4"><label>4</label><p id="P38">In some cases, patients received chemotherapy while molecular testing was pending.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>